美國食品藥物管理局採取行動，讓學名藥減肥藥距離上市更進一步
FDA move brings generic weight-loss drugs one step closer to market
多年來，受重量管理困擾的患者依賴著如 Wegovy 與 Ozempic 等 GLP-1 藥物。
For years, patients struggling with weight management have relied on GLP-1 medications like Wegovy and Ozempic.
由於嚴重短缺，美國食藥署 (FDA) 先前允許調配藥局生產未經批准的仿製藥品。
Because of severe shortages, the FDA previously allowed compounding pharmacies to produce unapproved copycat versions.
然而，FDA 為確保患者安全，已終止此項作法，因調配藥物缺乏官方產品嚴格的測試。
However, the FDA has since halted this practice to ensure patient safety, as compounded drugs lack the rigorous testing of official products.
2026 年 4 月，FDA 對學名藥版本的司美格魯肽 (semaglutide) 給予了暫定批准。
In April 2026, the FDA granted tentative approval for a generic version of semaglutide.
雖然這標誌著一個轉捩點，但真正的學名藥取得途徑仍受限於持續至 2028 年或更晚的專利保護。
While this marks a turning point, true generic access is still limited by patent protections that last until 2028 or later.
重要的是，須註意其間的差異：與調配藥物不同，學名藥必須經過 FDA 嚴格的安全與生物等效性審查。
It is important to note the difference: unlike compounded drugs, generics must undergo strict FDA review for safety and bioequivalence.
雖然製造這些複雜的多肽注射劑仍是一項重大的技術挑戰，但在專利到期的地區，全球市場已見到價格下降。
While manufacturing these complex peptide injections remains a significant technical challenge, the global market is already seeing lower prices where patents have expired.
在美國，患者仍面臨高昂成本，但這種監管進展為肥胖治療提供了一條邁向更實惠且可靠未來的有望途徑。
In the United States, patients continue to face high costs, but this regulatory progress offers a promising path toward a more affordable and reliable future for obesity treatment.
